首页 | 本学科首页   官方微博 | 高级检索  
     

超声引导经皮消融术治疗复发性肝癌
引用本文:谢晓燕,徐辉雄,吕明德,殷晓煜,匡铭,徐作峰,刘广健. 超声引导经皮消融术治疗复发性肝癌[J]. 中华普通外科杂志, 2005, 20(3): 143-145
作者姓名:谢晓燕  徐辉雄  吕明德  殷晓煜  匡铭  徐作峰  刘广健
作者单位:1. 510080,广州,中山大学第一附属医院超声科
2. 510080,广州,中山大学第一附属医院肝胆外科
摘    要:目的 评价超声引导经皮消融术对复发性肝癌的治疗作用。方法 对复发性肝细胞癌14 1例6 2 8个结节分别采用了经皮超声引导下微波、射频、酒精和沸腾蒸馏水消融治疗,观察局部、远期疗效和对肝功能的影响。结果 肿瘤完全消融率92 . 0 % (5 78/ 6 2 8) ,微波、射频、酒精和沸腾蒸馏水的完全消融率分别为96 3% (10 5 / 10 9)、92 . 9% (119/ 12 8)、91. 5 % (311/ 340 )和84. 3% (43/ 5 1)。本组治疗后局部复发率13 5 % (78/ 5 78) ,微波、射频、酒精和沸腾蒸馏水的局部复发率分别为11 .4 % (12 /10 5 )、13. 4 % (16 / 119)、11.9% (37/ 311)和30 . 2 % (13/ 4 3)。14 1例患者经2~6 6月随访,117例患者(81% )的肝功能无明显变化。1、3、5年累计生存率分别为75 %、5 3%、2 6 %。结论 经皮消融治疗复发性肝癌对肝功能损伤小,能有效控制局部病变发展和改善患者的预后。

关 键 词:肝肿瘤  超声  复发  消融
修稿时间:2004-03-15

Ultrasound-guided percutaneous ablation of recurrent hepatocellular carcinoma
XIE Xiao-yan,XU Hui-xiong,LU Ming-de,YIN Xiao-Yu,Kuang Ming,XU Zuo-feng,LIU Guang-jian. Ultrasound-guided percutaneous ablation of recurrent hepatocellular carcinoma[J]. Chinese Journal of General Surgery, 2005, 20(3): 143-145
Authors:XIE Xiao-yan  XU Hui-xiong  LU Ming-de  YIN Xiao-Yu  Kuang Ming  XU Zuo-feng  LIU Guang-jian
Abstract:Objective To evaluate ultrasound-guided percutaneous ablation for recurrent hepatocellular carcinoma.Methods In this study, 141 patients with recurrent hepatocellular carcinoma (628 lesions) were treated by percutaneous ablation therapies, including microwave, radiofrequency, ethanol injection and hot distilled water ablation.Results The complete ablation rate was 92.0% (578/628) in this group, and was 96.3% ( 105/109 )? 92.9%(119/128)? 91.5% (311/340) and 84.3% (43/51), respectively, for microwave, radiofrequency, ethanol and hot distilled water ablation subgroups.The local recurrence rate was 13.5% ( 78/578 ), and was 11.4% (12/105)? 13.4% (16/119)? 11.9% (37/311) and 30.2% (13/43), respectively, for microwave, radiofrequency, ethanol and hot distilled water ablation subgroups.After a follow-up period of 2-66 months, liver function remained unchanged in 117 patients (81%) after ablation therapies.Patients were followed-up for 2-66 months, the 1, 3 and 5-year survival rate was 75%, 53% and 26%, respectively.Conclusion Ultrasound-guided percutaneous ablation therapies for recurrent hepatocellular carcinoma are safe and effective, while incuring minimal damage to liver function and improving long-term survival.
Keywords:Liver neoplasms  Ultrasonography  Recurrence  Ablation
本文献已被 CNKI 维普 万方数据 等数据库收录!
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号